It appears to be a problem for tamiflu if the virus also has the other mutation which enables tamiflu resistance. Not an issue for Relenza.
Will be interesting to see how this development impacts stockpilers decision to buy more Relenza and/or accelerate Laninamivir and perhaps even flunet.
Overall, a pity Relenza appears tainted in some news articles which have failed to pick up the true story (as they did some years back) but this happens to favour Relenza.
Also saw some more investment in a GSK Relenza production facility...
